Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy

Table 2 Baseline clinicopathological characteristics of patients in early recurrence group and non-early recurrence group

Factors	Non-early recurrence group	Early recurrence group	X²	P value
Factors	n = 80	n = 81	X²	P value
Sex
Male	68	73	0.971	0.324
Female	12	8	0.971	0.324
Age (years)
≤ 55	39	42	0.155	0.694
> 55	41	39	0.155	0.694
AST (U/L)
≤ 40	60	58	0.237	0.626
> 40	20	23	0.237	0.626
ALT (U/L)
≤ 40	49	51	0.050	0.823
> 40	31	30	0.050	0.823
Total bilirubin (umol/L)
< 17.1	60	60	0.018	0.893
≥ 17.1	20	21	0.018	0.893
Albumin (g/L)
< 35	7	15	3.256	0.071
≥ 35	73	66	3.256	0.071
Tumour size (cm)
≤ 5	63	40	15.061	< 0.001
> 5	17	41	15.061	< 0.001
Tumour number
Solitary	73	61	7.328	0.007
Multiple	7	20	7.328	0.007
HBV infection
No	6	6	0.001	0.982
Yes	74	75	0.001	0.982
Liver cirrhosis
No	21	20	0.052	0.820
Yes	59	61	0.052	0.820
Vascular invasion
No	75	57	14.897	< 0.001
Yes	5	24	14.897	< 0.001
Differentiation
Moderate and well	61	37	15.793	< 0.001
Poor	19	44	15.793	< 0.001
Blood transfusion
No	48	46	0.171	0.680
Yes	32	35	0.171	0.680
Hepatic hilar occlusion
No	41	40	0.056	0.813
Yes	39	41	0.056	0.813
SII
≤ 330	57	51	1.252	0.263
> 330	23	30	1.252	0.263
MLR
≤ 0.25	49	16	28.790	< 0.001
> 0.25	31	65	28.790	< 0.001
NLR
≤ 2.74	71	55	10.283	0.001
> 2.74	9	26	10.283	0.001
PLR
≤ 88	54	41	4.743	0.029
> 88	26	40	4.743	0.029
SIRI
≤ 1.03	60	42	9.289	0.002
> 1.03	20	39	9.289	0.002
AFP (ng/mL)
< 400	65	53	5.145	0.023
≥ 400	15	28	5.145	0.023
ALBI grade
1	47	40	1.422	0.233
2	33	41	1.422	0.233
BCLC stage
0–A	68	47	14.351	< 0.001
B–C	12	34	14.351	< 0.001

AST aspartate aminotransferase, ALT alanine aminotransferase, HBV hepatitis B virus, AFP alpha fetoprotein, ALBI albumin–bilirubin, BCLC Barcelona Clinic Liver Cancer

ISSN: 1471-2482